Long‐term weight loss and cardiorenal outcomes by baseline <scp>BMI</scp> in the <scp>VERTIS CV</scp> trial
Weight loss was observed across baseline BMI and was sustained over 5 years of follow-up. The effects of ertugliflozin on HHF and kidney composite were consistent across baseline BMI.
Authors
- Christopher P. Cannon (ORCID: https://orcid.org/0000-0003-4596-2791)
- Ira Gantz (ORCID: https://orcid.org/0000-0002-6565-7113)
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Samuel E. Dagogo-Jack (ORCID: https://orcid.org/0000-0001-5318-9677)
- Robert Frederich (ORCID: https://orcid.org/0000-0002-5175-3112)
- Willy Wynant (ORCID: https://orcid.org/0000-0001-7014-3515)
- Richard E. Pratley (ORCID: https://orcid.org/0000-0002-2912-1389)
- Nilo B. Cater (ORCID: https://orcid.org/0000-0001-5868-8643)
- Francesco Cosentino (ORCID: https://orcid.org/0000-0002-6967-5685)
- Aiwen Xing (ORCID: https://orcid.org/0000-0003-4901-7025)
- James P. Mancuso (ORCID: https://orcid.org/0000-0002-5722-1360)
Institutions
- Brigham and Women's Hospital (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University Health Network (CA)
- Karolinska University Hospital (SE)
- Harvard University (US)
- University of Tennessee Health Science Center (US)
- Pfizer (United States) (US)
- University of Toronto (CA)
- Karolinska Institutet (SE)
- Syneos Health (United States) (US)
- Decision Sciences (United States) (US)
- Translational Research Institute for Metabolism and Diabetes (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1111/dom.16050
- Citations
- 2
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Pfizer